Prolacta Bioscience, Inc.

City of Industry, CA

UEI
VJUKD4ELEKD6
CAGE
5K9M8
Primary NAICS
325414 Biological Product (except Diagnostic) Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
757 Baldwin Park Blvd, City of Industry, CA 91746, USA
Website
prolacta.com
Founded
1999
Employees
51-250
Estimated annual revenue
$10M-$50M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $293,575
FY2025 $170,087
FY2024 $803,636
FY2023 $1,278,000

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Defense Health Agency $293,575

Contract awards

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Hollandia Dairy, Inc. UEI VBBDFMAHLJV6 San Marcos, CA 311511 Fluid Milk Manufacturing
International Biomedical, LTD. UEI LLKWNSZZLJC4 Austin, TX 339112 Surgical and Medical Instrument Manufacturing
Cream-O-Land Dairies UEI CKLJG19DNKB7 Florence Township, NJ 311511 Fluid Milk Manufacturing
Oak Farms Dairy UEI X16BL7K2L8V7 Houston, TX 311511 Fluid Milk Manufacturing
Shamrock Foods Company UEI CKH1YKS92TN3 Phoenix, AZ 112120 Dairy Cattle and Milk Production

About the company

Prolacta Bioscience, Inc., headquartered in City of Industry, California, manufactures pasteurized human milk-based nutritional products for neonatal intensive care units as a prime contractor to the Defense Health Agency and Department of Defense medical commands, competing on a full-and-open basis with no set-aside designations across its federal portfolio.

Prolacta is a for-profit manufacturer of goods specializing exclusively in human milk-derived fortifiers, donor human milk, breastmilk supplementation products, and pre-natal infant formulas engineered for extremely low birth weight and critically ill newborns. The company's federal footprint is narrowly focused on military healthcare: all 72 awards in the source data are prime contracts with the Defense Health Agency, the Department of the Army Medical Command, and the Department of the Navy Bureau of Medicine and Surgery, with zero subcontract exposure. Representative work includes a $113,211 BPA call from the Defense Health Agency in March 2026 for pasteurized human milk products; a $24,971 order in November 2025 for breastmilk fortification products at Tripler Army Medical Center; and a $150,000 BPA call from the Department of the Army Medical Command in October 2021 for human milk-based neonatal nutrition products. The company's categorization by NAICS centers on Biological Product Manufacturing (70 awards), with secondary coding in Surgical and Medical Instrument Manufacturing and Special Dietary Foods.

Customer concentration is extreme. The Defense Health Agency accounts for 50 awards and $9.9 million in combined potential value (100% coverage across both award-count and dollar rankings); the Department of the Army Medical Command holds 14 awards worth $6.3 million; and the Department of the Navy Bureau of Medicine and Surgery represents 8 awards worth $1.1 million. The rankings align perfectly, signaling no tension between volume and value—DHA dominates both dimensions. Prolacta operates under three single-award BPAs with the Defense Health Agency: a $1.75 million agreement established in October 2022 with ultimate completion in September 2027; a $1.9 million agreement awarded in December 2024 running through December 2029; and a $500,000 agreement from September 2023 expiring September 2028. Two Army Medical Command BPAs generate the bulk of remaining activity: Blanket Purchase Agreement W81K0222A0010 has generated 27 task orders worth $1.2 million combined potential value, and Blanket Purchase Agreement W81K0217A0025 has produced 12 task orders worth $1 million.

Activity trajectory shows volatility within a small envelope: 7 awards in 2022, climbing to 12 in 2023, declining to 9 in 2024, dropping to 8 in 2025, and 2 awards through mid-2026. Combined potential value across the entire portfolio totals $17.4 million, with $8.9 million obligated (51% realization rate). The recompete cliff is minimal—only 3 awards with ultimate completion dates within the next twenty-four months carry a combined potential value of $86 thousand, presenting negligible near-term recompete exposure. Prolacta holds no government-wide vehicles, agency-wide IDIQs, GWACs, or GSA Schedules; all federal work flows through single-award BPAs held directly with military health system customers. The company has not appeared as a subcontractor in the source data, and no primes name Prolacta as a sub. Prolacta's federal business model is a sole-source or near-sole-source specialty supplier to neonatal units within the military healthcare system, with no diversification across civilian agencies, no teaming or subcontracting relationships, and no pursuit pathway outside DHA and Army Medical Command medical facilities.

Quick answers

Is Prolacta Bioscience, Inc. registered in SAM.gov?

Yes. Prolacta Bioscience, Inc.'s SAM.gov registration is active through May 19, 2027.

How much has Prolacta Bioscience, Inc. received in federal contracts?

Federal contracts obligated $170,087 to Prolacta Bioscience, Inc. in fiscal year 2025 and $2,545,297 in fiscal years 2023 through 2027.

How does Prolacta Bioscience, Inc. rank among federal contractors?

Prolacta Bioscience, Inc. ranked #46 in NAICS 325414 and #87 in PSC 6850 in FY2025.

What is Prolacta Bioscience, Inc.'s most recent federal award?

Prolacta Bioscience, Inc.'s most recent federal contract award is Additional prolacta breastmilk supplementation products to support 7 extremely premature and low birth weight infants… (HT009026FL115), from Defense Health Agency, on July 23, 2026.

On GovTribe

See Prolacta Bioscience, Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors